← Home
Abbott Laboratories 
Healthcare & biotech / Diversified healthcare products
Press Releases
| Date | Press release |
|---|---|
| 2025-05-01 09:00:00 | Motoamerica Becomes First Sports Organization To Use Abbott’s Rapid Blood Test For Concussion Evaluation On-site At Races The test, run on abbott’s portable i-stat ® alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutes the test will be used by healthcare professionals in the medical facilities at all motoamerica races in 2025 abbott park, ill., and irvine, calif. |
| 2025-04-29 09:05:00 | Abbott Integrates Libre’s Data With Epic’s Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information Collaboration brings together freestyle libre® systems, the world’s leading continuous glucose monitoring technology (cgm)1 with epic, a healthcare software company, to streamline access to cgm data for healthcare organizations integration empowers u.s. clinicians to enhance patient care by incorporating libre’s data directly into their workflows abbott park, ill., april 29, 2025 /prnewswire/ -- abbott (nyse: abt), the global leader in continuous glucose monitoring (cgm) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 libre cgm systems directly into epic’s electronic health record systems in the u.s. the collaboration aims to improve workflow efficiency for providers through epic’s aura software, which brings health systems together with diagnostics labs and medical device manufacturers. |
| 2025-04-27 14:15:00 | Abbott Highlights New Aveir™ Data, Initiates Trial For The Company’s Conduction System Pacing Technology Late-breaking data from abbott’s groundbreaking first-in-human study demonstrated successful implantation of the company’s aveir conduction system pacing (csp) leadless pacemaker enrollment has also begun in the ascend csp pivotal clinical trial to evaluate abbott’s investigational csp implantable cardioverter-defibrillator (icd) lead conduction system pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm san diego , april 27, 2025 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking data from the aveir™ conduction system pacing (csp) acute clinical feasibility study, which demonstrated the safety and performance of the investigational aveir csp leadless pacemaker technology. the aveir csp acute clinical feasibility study is the world’s first assessment of a leadless pacemaker delivering conduction pacing to the heart’s left bundle branch (lbb) area. |
| 2025-04-26 19:15:00 | New Clinical Study Data Showcase Long-term, Sustained Benefits Of Abbott’s Volt™ Pfa System For Patients With Afib Long-term data from the volt ce mark study show strong results out to 12 months in patients receiving pulsed field ablation (pfa) therapy with the volt™ pfa system the 12-month results of the volt ce mark study confirm the long-term safety and efficacy of the volt pfa system the data were presented at the 2025 heart rhythm society (hrs) annual meeting abbott park, ill., april 26, 2025 /prnewswire/ -- abbott (nyse: abt) has announced new data from its volt ce mark study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (pfa) therapy with the volt™ pfa system for the treatment of atrial fibrillation (afib). |
| 2025-04-16 07:30:00 | Abbott Reports First-quarter 2025 Results And Reaffirms Full-year Guidance First-quarter gaap diluted eps of $0.76; adjusted diluted eps of $1.09 first-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding covid-19 testing-related sales1 reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increase reported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increase abbott park, ill., april 16, 2025 /prnewswire/ -- abbott (nyse: abt) today announced financial results for the first quarter ended march 31, 2025. |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal